Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Financial Information Relating to Reportable Segments (Details)

v3.4.0.3
Note 3 - Financial Information Relating to Reportable Segments (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Biotechnology [Member] | Operating Segments [Member]        
Net sales $ 81,386,000 $ 78,521,000 $ 232,984,000 $ 229,347,000
Operating income 45,133,000 44,620,000 124,436,000 122,967,000
Clinical Controls [Member] | Operating Segments [Member]        
Net sales 29,929,000 20,001,000 76,013,000 56,417,000
Operating income 9,454,000 6,186,000 21,464,000 17,422,000
Protein Platforms [Member] | Operating Segments [Member]        
Net sales 19,693,000 15,669,000 55,327,000 49,061,000
Operating income 1,592,000 (1,710,000) 1,948,000 4,461,000
Operating Segments [Member]        
Operating income 56,179,000 49,096,000 147,848,000 144,850,000
Intersegment Eliminations [Member]        
Net sales (35,000) (33,000) (63,000) (242,000)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative (664,000) (399,000) (2,820,000) (2,408,000)
Acquisition Related [Member]        
Amortization expense (7,276,000) (6,751,000) (22,048,000) (19,337,000)
Net sales 130,973,000 114,158,000 364,261,000 334,583,000
Operating income 43,527,000 39,426,000 110,581,000 109,222,000
Costs recognized on sale of acquired inventory (1,082,000) (897,000) (3,439,000) (5,252,000)
Amortization expense     (22,443,000)  
Acquisition related expenses (1,313,000) (335,000) (2,284,000) (3,906,000)
Stock based compensation (2,317,000) (1,288,000) (6,676,000) (4,725,000)
Corporate general, selling, and administrative $ (35,217,000) $ (29,089,000) $ (102,842,000) $ (88,927,000)